Key Messages•Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiologic agent of the coronavirus disease 19 pandemic, enters cells by binding to angiotensin-converting enzyme 2 on cell surfaces.•Beyond the lungs, the virus can infect the kidney, causing acute injury.•Angiotensin-converting enzyme 2 expression is increased approximately 2-fold in diabetic kidney disease biopsies.

Introduction {#sec1}
============

Diabetes is associated with an adverse outcome, including death, after coronavirus disease 19 (COVID-19) infection ([@bib1]); however, whether it also increases susceptibility to infection is unknown. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiologic agent of the pandemic, binds to the cell surface ectoenzyme, angiotensin-converting enzyme (ACE) 2, the abundance of which may be a determinant of virus entry and vulnerability to infection ([@bib2]). Recent studies have identified the kidney as a site of infection by SARS-CoV-2 ([@bib3]), and have highlighted acute kidney injury as a common adverse outcome in patients with severe COVID-19 disease ([@bib4]). Although hemodynamic imbalance and cytokine release are likely contributors to the acute loss of kidney function, the ability of SARS-CoV-2 to infect kidney cells and to induce immunologic injury and microthrombus formation ([@bib5]) suggests that the virus itself may be directly involved ([@bib6]).

Substantial advances have been made in the assessment of gene expression in kidney biopsies, focusing in particular on site-specific changes in glomeruli and to a lesser extent tubules ([@bib7]). ACE 2, however, is highly expressed in macrophages ([@bib8]) and in the microvasculature ([@bib9]) that resides in the interstitial space and traditionally not subjected to selective laser capture microscopic microdissection of the kidney ([@bib7]). Accordingly, we sought to examine the abundance of ACE 2 in whole rather than microdissected biopsy tissue from individuals with diabetic kidney disease.

Methods {#sec2}
=======

After approval from the St. Michael's Hospital research ethics board, our centre compiled a biobank of archived kidney biopsies from which to conduct molecular analyses. Seventy-three patients with a clinical diagnosis of diabetes and a pathologic diagnosis of diabetic nephropathy on biopsy from January 2007 to September 2016 at St. Michael's Hospital were reviewed. All biopsies sampled the renal cortex. Of these, 49 showed only diabetic kidney disease and had adequate documentation of their clinical status and medications at the time of the biopsy with emphasis on their use of agents that block the renin-angiotensin-aldosterone system (RAAS), including ACE inhibitors, angiotensin receptor blockers (ARBs), direct renin inhibitors (DRIs) or mineralocorticoid receptor antagonists (MRAs). Glycated hemoglobin measurements within 3 months of the biopsy were available in 32 participants. Kidney biopsies from healthy control subjects were obtained from 12 potential living allograft donors.

To assess the transcriptome in these biopsies, ten 10-μm-thick sections were cut from formalin fixed paraffin-embedded kidney biopsy blocks or from fresh frozen tissue embedded in Cryomatrix (BD Biosciences, Canada). Total RNA was extracted, ribosomal RNA was removed, and complementary DNA libraries were then prepared and quantitated prior to RNA sequencing (Illumina HiSeq 3000), as previously reported ([@bib10]). Abundance of ACE 2 messenger RNA was then determined and analyzed according to whether patients were receiving an agent that blocked the RAAS: ACE inhibitors, ARBs, DRIs or MRAs.

Statistical analysis {#sec2.1}
--------------------

Data are expressed as mean ± SD, unless otherwise stated. The magnitude of gene expression in control and diabetic kidney disease biopsies was compared using an unpaired Student t test. Within the diabetic kidney disease group, expression levels between those receiving and not receiving treatment with an agent that blocks the RAAS were similarly compared using an unpaired Student t test. p\<0.05 was considered significant.

Results {#sec3}
=======

At the time of biopsy, approximately three-quarters (38 of 49) of those with diabetic kidney disease were receiving therapy with at least 1 agent that blocks the RAAS: 25 as single agent ACE inhibitor, ARB or MRA treatment with 11 prescribed dual therapy and a further 2 receiving triple ACE, ARB and MRA combination treatment ([Table 1](#tbl1){ref-type="table"} ). As in most other sites, there were more men than women in the diabetic kidney disease group with the reverse pattern seen in the control, living allograft donors.Table 1Clinical data on patients with diabetic kidney disease and healthy control subjects (potential allograft donors)Clinical parametersPatients with diabetic kidney disease (n=49)Healthy control subjects (n=12)Age, years56±1047±9% female3392Duration of diabetes, years14±9N/AHbA1c, mmol/mol, %66.1; 8.2%±2.3%Baseline estimated glomerular filtration rate, mL/min/1.73 m^2^40±2289±13Baseline urine albumin to creatinine ratio, mg/mmol337±3220.8±0.9Medication usage RAAS nonusers11N/A RAAS users38 DRI only0 ACEi only12 ARB only12 MRA only1 DRI + ACEi3 DRI + ARB1 DRI + MRA0 ACEi + ARB5 ACEi + MRA1 ARB + MRA1 ACEi + ARB + MRA2[^1][^2]

The magnitude of ACE 2 gene expression in biopsies obtained from patients with diabetic kidney disease varied widely when compared with that found in biopsies from healthy control subjects. The variability notwithstanding, mean ACE 2 messenger RNA was increased approximately 2-fold in diabetes when compared with healthy control subjects ([Figure 1](#fig1){ref-type="fig"} , [Supplementary Table 1](#tblS1){ref-type="table"}), whereby mean expression of ACE 2 was 13.2±7.9 reads per million reads (RPMs) in biopsies from subjects with diabetic kidney disease and 7.7±3.6 RPMs in those from control subjects (p=0.001). No difference in transcript abundance was noted between recipients and nonrecipients of agents that block the RAAS (12.2±6.7 vs 16.2±10.7 RPMs, respectively; p=0.25) or among those receiving treatment with an ACE inhibitor, ARB, DRI, diuretic or MRA ([Figure 2](#fig2){ref-type="fig"} ). Similarly, we found no relationship between ACE 2 copy number and either glycated hemoglobin (Spearman rho = 0.05; p=0.8), or between ACE 2 copy number and estimated glomerular filtration rate (ρ=0.10, p=0.5).Figure 1Violin plots showing ACE2 mRNA expression as transcript union RPMs in kidney biopsies from individuals with diabetic kidney disease (purple) and living allograft donors (red) with ACE2 expression in diabetic samples also assessed according to use (blue) or not (green) of agents that block the RAAS: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, direct renin inhibitors and mineralocorticoid receptor antagonists. *ACE2,* angiotensin-converting enzyme 2; *mRNA,* messenger RNA; *RAAS,* renin-angiotensin-aldosterone system; *RPM,* reads per million read.Figure 2Box plots showing ACE2 mRNA expression as transcript union RPMs in kidney biopsies from individuals with diabetic kidney disease assessed according to use of ACEis, ARBs, DRIs, diuretics and MRAs. *ACE2,* angiotensin-converting enzyme 2; *ACEi,* angiotensin-converting enzyme inhibitor; *ARB,* angiotensin receptor blocker; *DRI,* direct renin inhibitor; *MRA,* mineralocorticoid receptor antagonist; *mRNA,* messenger RNA; *RPM,* reads per million read.

Discussion {#sec4}
==========

An increase in ACE 2 expression in the setting of diabetic kidney disease raises the possibility that such individuals may be at higher risk of kidney infection with SARS-CoV-2 in COVID-19 disease, potentially increasing the risk of acute kidney injury and death. Furthermore, the study provides reassurance that any propensity to infection should not be exacerbated by concomitant use of agents that block the RAAS.

The main strengths of this study are the number of biopsies examined, the state-of-the-art technology used to quantify gene expression and the documentation of medications taken at the time of biopsy. We found only a single published study that compared ACE 2 messenger RNA in kidney biopsies from patients with diabetes with that of healthy control subjects using robust methodology (quantitative polymerase chain reaction) ([@bib7]). In contrast with the current study of 49 biopsies, the number of biopsies in the study by Reich et al ([@bib7]) was comparatively small, examining only 13 biopsies from patients with diabetes and showing a reduction in expression in diabetes. Moreover, unlike our study, the use of laser capture of proximal tubules and glomeruli in the latter study would not have fully taken into account the abundant ACE 2 expression in infiltrating cells, the postglomerular vasculature and nephron segments beyond the proximal tubule that may display differential expression in diabetes ([@bib11]). Indeed, macrophages and pericytes have been shown to express high levels of ACE 2, suggesting that these cells may be particularly vulnerable to SARS-CoV-2 infection ([@bib8]). In addition, the use of next-generation RNA Seq technology enabled a true measurement of ACE 2 transcript levels, as opposed to the relative levels generated by semiquantitative polymerase chain reaction or microarray-based techniques. Finally, archived remnants of formalin-fixed paraffin-embedded core biopsies have not generally been used for RNA Seq because the yield and quality of RNA from such small tissue samples has been insufficient for RNA sequencing. Our technology, developed in bladder tumours ([@bib10]), overcame these limitations, enabling us to examine ACE 2 expression in small, residual amounts of clinically indicated renal biopsy samples.

In spite of the large number of biopsy specimens studied and reliance on whole rather than microdissected tissue, our study does, however, have several limitations. Most notably, the study was confined to the examination of kidney tissue and not lungs, the principal site of COVID-19 infection. Moreover, having studied only patients with biopsy-proven diabetic kidney disease, we are unable to make any inferences on whether the changes in ACE 2 messenger RNA observed in the current study apply to other organs, most notably the lungs, or if the changes in ACE 2 expression seen in our study group also apply to the kidneys of individuals with diabetes and normal kidney function. In addition, the current study which assessed gene expression in sections cut from kidney biopsies was unable to determine cell-specific patterns of expression that may have differentially affected parenchymal, vascular and inflammatory cells. Finally, although the abundance of a receptor required for SARS-CoV-2 entry was examined, many more components of the cell machinery are required for the virus to infect a cell, initiate virus replication and kill its host; although we assessed gene expression, its translation into protein was not examined.

Diabetes is a well-known risk factor not only for severe bacterial infections, but also for viral infections, such as H1N1 influenza ([@bib12]). As was the case in previous human coronavirus infections, such as severe acute respiratory syndrome and Middle East respiratory syndrome, individuals with diabetes are also at higher risk of adverse outcomes with COVID-19 ([@bib13]). Although this may reflect a generalized predisposition to poor outcome with infectious diseases, it may also be a consequence of an increased propensity for cellular entry and invasion by SARS-CoV-2, while noting that the current study assessed ACE 2 gene expression in the kidney and not in the lungs.

Interaction between a virus and its host cells are key determinants of infection severity. For instance, studies of a related murine coronavirus showed a dose-dependent relationship between the number of infective virus particles and the likelihood of death ([@bib14]). Tissue-specific viral receptor abundance may also influence infectivity ([@bib11]) and thereby contribute to the extrapulmonary manifestations of COVID-19, such as kidney and vascular disease. Consistent with this clinical observation, single cell RNA sequencing identified cells in the lung, kidney and heart as major sites of ACE 2 expression ([@bib2]). Accordingly, the augmented kidney ACE 2 expression demonstrated in the present study may signify a greater propensity to renal complications of COVID-19 among individuals with diabetes.

A number of recently published observational studies concluded that the use of agents that block the RAAS increased neither the propensity to infection nor the likelihood of an adverse outcome ([@bib15], [@bib16], [@bib17]). Although these studies did not specifically examine whether this broad conclusion also applied to individuals with diabetes, the current study does not indicate any relationship between the use of agents that block the RAAS and ACE 2 expression in the diabetic setting.
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Appendix {#appsec3}
========

Supplementary Table 1Quality control meta-data for RNA Seq analysis of ACE 2 expressionIDACE 2 RPMACE 2 count (raw read number)Raw read count from fastqcMapped read numbersFinal unique read numbersMapping % (mapped reads/raw reads from fastqc)Unique reads/mapped reads (%)Unique reads/raw reads (%)ConditionS111.881,166101,465,08298,099,05482,972,02796.68257584.579844281.77397127DKDS1032.353,808126,566,284117,684,06398,667,86592.9821586683.841314277.95746377DKDS113.36642188,577,850190,596,410159,468,358101.07041283.668080684.56367384DKDS125.36520114,244,96896,992,73766,805,46584.8989138868.876770658.47563019DKDS136.21808175,045,896129,964,89797,959,48774.2461834175.373804255.96217291DKDS146.29819137,316,374130,057,55599,596,71394.7137993976.578952372.53083525Normal ControlS1519.772,454125,973,470124,069,715106,369,18698.4887651385.733400884.43776773DKDS172.98338114,739,886113,279,46392,896,43098.7271880382.006418180.96263055Normal ControlS186.32797131,967,904125,958,05298,037,37095.445974577.833348874.28879828Normal ControlS1918.672,234125,828,736119,626,46192,277,03095.0708596577.13764173.33541839DKDS232.653,358107,149,218102,835,83181,401,80495.9744111279.15704475.97050685DKDS2014.051,630121,341,514116,008,43394,539,79595.604899981.493898877.91216038DKDS2110.461,168114,541,108111,565,72387,783,59597.402343178.683302276.63937999DKDS2313.161,886153,494,604143,258,910123,152,44693.3315610285.96494780.23242693DKDS247.581,263176,090,214166,535,504132,321,42794.5739687779.455385775.14411164DKDS265.13595121,143,542115,801,42496,940,37495.5902577183.712592380.02108276DKDS2813.281,584127,927,852119,193,00393,410,71693.172050678.369294973.01827908Normal ControlS298.961,094124,756,622122,075,55598,496,72797.8509621780.685053678.95110129Normal ControlS319.641,911108,050,09297,254,21873,226,93090.008454675.294348767.77127964DKDS304.35469116,072,918107,717,08572,359,38992.8012208767.175405862.33959674Normal ControlS315.81599126,222,334102,977,82076,401,40281.5844682474.19209560.52922615DKDS3237.613,643103,394,49296,860,28185,553,78293.6803103688.327001782.74500928DKDS339.951,149124,113,112115,461,620101,243,71893.0293489187.686036381.57374863DKDS346.1723128,575,262118,359,20693,275,37192.0544155778.807026672.5453478Normal ControlS3513.451,796136,947,722133,454,499102,748,76897.4492288476.991610575.02773065Normal ControlS3612.311,252106,491,158101,699,95176,515,28595.5008405575.236304771.85130337DKDS386.34660108,149,060104,020,50986,927,17296.182536483.567339680.37718682DKDS49.09892105,342,07298,043,41383,559,52893.0714681685.227069879.3220851DKDS4022.442,083102,534,85292,791,32980,415,71490.4973549986.662961878.42768818DKDS435.82717129,310,302123,119,60291,843,51895.2125237574.596990771.02567744Normal ControlS4710.531,301125,599,084123,536,43697,933,17098.3577523579.274725177.97283776Normal ControlS4811.091,358129,861,432122,361,65688,440,72694.2247856972.278137568.10392018Normal ControlS4919.562,664140,716,858136,163,725113,595,35096.7643301183.425559980.72618421DKDS520.662,525129,277,952122,208,25792,915,79894.5313992976.030703971.87288827DKDS508.471,178145,194,772138,993,857122,500,83495.7292436188.133991484.37000335DKDS518.621,009121,066,116117,037,226103,152,22596.6721572288.136252585.20321656DKDS525.79664119,156,404114,491,282100,216,84196.0848751487.5322984.10529156DKDS5310.781,439140,139,922133,387,449117,250,40695.1816206987.902127983.66666994DKDS5412.341,677138,605,802135,790,629116,695,94297.9689356785.938140884.19268192DKDS5510.681,134108,659,548106,132,29185,310,69197.6741510180.381465678.51191411DKDS5615.241,993128,886,930130,769,14994,009,761101.460364571.889862272.93971623DKDS5720.153,081151,341,932152,896,130126,284,590101.026944782.595020683.44322577DKDS5813.21,746131,157,148132,245,79091,054,983100.830028768.852840669.42433896DKDS596.191,056170,223,200170,469,398120,482,742100.144632570.677050270.77927216DKDS6014.121,667121,045,880117,986,53589,261,89697.4725740475.654307573.74220089DKDS619.11,198135,099,374131,562,506105,719,70997.3820248880.357019878.25329302DKDS622.64366135,216,050138,598,101107,703,422102.501220177.709161479.65283855DKDS635.95786133,282,782132,057,096107,361,86499.0803868481.299579780.55193806DKDS6410.731,520146,982,650141,617,337121,123,92096.3496963885.529019782.40695075DKDS6523.042,726121,592,562118,315,22297,936,48297.3046542182.775893480.54479681DKDS662.11371173,153,814175,225,951137,535,251101.196703178.490229579.42952443DKDS67172,612147,157,566153,576,126115,308,540104.361692175.082334178.35719436DKDS6819.12,359124,788,568123,450,100102,452,23998.9274113682.990810982.10066086DKDS6911.191,781160,522,214159,145,496135,084,19299.1423504884.880939484.15295842DKDS73.72550146,984,322147,547,677120,541,988100.383275681.696974582.01009901Normal ControlS7012.691,689133,615,280133,031,354107,608,62799.5629796280.889672880.53616847DKDS7114.182,045140,677,196144,153,124111,566,950102.470853977.3947579.30706125DKDS726.011,634281,300,140271,680,124207,399,30596.5801595476.339520973.72883106DKDS734.77483123,833,718101,246,37961,657,13381.7599444160.898111749.79026229DKDS824.022,450103,952,142101,965,13379,035,11798.0885348277.51190576.0302919DKDS913.91,671130,740,442120,131,959109,764,11391.8858443291.369618883.95574569DKD[^3]
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[^1]: *ACEi,* angiotensin-converting enzyme inhibitor; *ARB,* angiotensin receptor blocker; *DRI,* direct renin inhibitor; *HbA1C,* glycated hemoglobin; *MRA,* mineralocorticoid receptor antagonist; *N/A,* not applicable; *RAAS,* renin-angiotensin-aldosterone system.

[^2]: *Note:* All values are presented as mean ± SD, number of patients or as otherwise indicated.

[^3]: *ACE 2,* angiotensin-converting enzyme 2; *DKD*, diabetic kidney disease; *ID,* identification; *RPM,* reads per million read.
